Caribou BiosciencesCRBU
CRBU
About: Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies.
Employees: 137
0
Funds holding %
of 6,823 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
107% more call options, than puts
Call options by funds: $344K | Put options by funds: $166K
100% more funds holding in top 10
Funds holding in top 10: 1 [Q2] → 2 (+1) [Q3]
27% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 33
16% more capital invested
Capital invested by funds: $89.4M [Q2] → $104M (+$14.6M) [Q3]
1.62% less ownership
Funds ownership: 60.06% [Q2] → 58.44% (-1.62%) [Q3]
9% less funds holding
Funds holding: 140 [Q2] → 128 (-12) [Q3]
36% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 28
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$6
297%
upside
Avg. target
$8.67
474%
upside
High target
$11
628%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
B of A Securities Alec Stranahan 0% 1-year accuracy 0 / 6 met price target | 628%upside $11 | Buy Maintained | 7 Jan 2025 |
Citigroup Yigal Nochomovitz 27% 1-year accuracy 12 / 45 met price target | 297%upside $6 | Buy Maintained | 26 Nov 2024 |
HC Wainwright & Co. Robert Burns 23% 1-year accuracy 37 / 160 met price target | 496%upside $9 | Buy Reiterated | 15 Nov 2024 |
Financial journalist opinion
Based on 197 articles about CRBU published over the past 30 days
Neutral
Accesswire
3 hours ago
Caribou Biosciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before February 24, 2025 to Discuss Your Rights - CRBU
NEW YORK, NY / ACCESS Newswire / January 22, 2025 / If you suffered a loss on your Caribou Biosciences, Inc. (NASDAQ:CRBU) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/caribou-biosciences-inc-lawsuit-submission-form?prid=124311&wire=1 or contact Joseph E. Levi, Esq.
Neutral
Accesswire
4 hours ago
CRBU INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Caribou Biosciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Caribou Biosciences, Inc. ("Caribou" or "the Company") (NASDAQ:CRBU) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Caribou securities between July 14, 2023 and July 16, 2024, both dates inclusive (the "Class Period").
Neutral
Accesswire
15 hours ago
Levi & Korsinsky Reminds Caribou Biosciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 24, 2025 – CRBU
NEW YORK CITY, NY / ACCESS Newswire / January 21, 2025 / If you suffered a loss on your Caribou Biosciences, Inc. (NASDAQ:CRBU) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/caribou-biosciences-inc-lawsuit-submission-form?prid=124233&wire=1 or contact Joseph E. Levi, Esq.
Neutral
Accesswire
16 hours ago
ROSEN, LEADING INVESTOR COUNSEL, Encourages Caribou Biosciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CRBU
NEW YORK, NY / ACCESS Newswire / January 21, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Caribou Biosciences, Inc. (NASDAQ:CRBU) between July 14, 2023 and July 16, 2024, both dates inclusive (the "Class Period"), of the important February 24, 2025 lead plaintiff deadline. SO WHAT: If you purchased Caribou securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Neutral
Accesswire
16 hours ago
Shareholders that lost money on Caribou Biosciences, Inc.(CRBU) should contact Levi & Korsinsky about pending Class Action - CRBU
NEW YORK, NY / ACCESSWIRE / January 21, 2025 / If you suffered a loss on your Caribou Biosciences, Inc. (NASDAQ:CRBU) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/caribou-biosciences-inc-lawsuit-submission-form?prid=124212&wire=1 or contact Joseph E. Levi, Esq.
Neutral
GlobeNewsWire
19 hours ago
CRBU INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Caribou Biosciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
NEW YORK, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Caribou Biosciences, Inc. (“Caribou” or “the Company”) (NASDAQ: CRBU) and certain of its officers.
Neutral
Accesswire
20 hours ago
Lost Money on Caribou Biosciences, Inc. (CRBU)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
NEW YORK CITY, NY / ACCESS Newswire / January 21, 2025 / If you suffered a loss on your Caribou Biosciences, Inc. (NASDAQ:CRBU) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/caribou-biosciences-inc-lawsuit-submission-form?prid=124166&wire=1 or contact Joseph E. Levi, Esq.
Neutral
PRNewsWire
20 hours ago
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Caribou Biosciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - CRBU
NEW YORK , Jan. 21, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Caribou Biosciences, Inc. ("Caribou" or the "Company") (NASDAQ: CRBU) and certain officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 24-cv- 09413 is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Caribou securities between July 14, 2023 and July 16, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
Neutral
Accesswire
21 hours ago
Investors Who Lost Money on Caribou Biosciences, Inc. (CRBU) Should Contact Levi & Korsinsky About Pending Class Action - CRBU
NEW YORK, NY / ACCESS Newswire / January 21, 2025 / If you suffered a loss on your Caribou Biosciences, Inc. (NASDAQ:CRBU) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/caribou-biosciences-inc-lawsuit-submission-form?prid=124125&wire=1 or contact Joseph E. Levi, Esq.
Neutral
GlobeNewsWire
22 hours ago
Investors who lost money on Caribou Biosciences, Inc.(CRBU) should contact The Gross Law Firm about pending Class Action - CRBU
NEW YORK, Jan. 21, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Caribou Biosciences, Inc. (NASDAQ: CRBU).
Charts implemented using Lightweight Charts™